NSABP Members' Area
  Password Protected - Access
  Limited to NSABP Participating
  Institutions Only

NSABP Foundation, Inc.

General NSABP Information
  Financial Conflicts of
     Interest Policy
  Contact the NSABP

Clinical Trials Information
  Clinical Trials Overview
  Protocol Chart
  Never Say Lost

Treatment Trials Information
  Protocol B-51
  Protocol B-52
  Protocol B-53/S1207
  Protocol B-55/BIG 6-13

Prevention Trials Information
  Protocol P-1 - BCPT
  Protocol P-2 - STAR

To report problems, ask
questions or make comments,
please send e-mail to:

NSABP Clinical Trials Overview

Protocol B-11
A Protocol to Compare L-PAM and 5-FU With and Without Adriamycin in the Management of Primary Breast Cancer Patients with Positive Axillary Nodes Whose Tumors are Negative for Estrogen Receptors and/or Progesterone Receptors

Specific Aims
To determine whether L-PAM + 5-FU + Adriamycin (PAF) is more effective than L-PAM + 5-FU (PF) in disease-free survival and survival of patients with one or more positive nodes whose tumors are estrogen-receptor (ER) negative and/or progesterone-receptor (PR) negative.